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Abstract
Background: Angelman syndrome (AS) is a neurodevelopmental disorder caused by mutations affecting
UBE3A function. AS is characterized by intellectual disability, impaired motor coordination, epilepsy, and
behavioral abnormalities including autism spectrum disorder features. The development of treatments for AS
heavily relies on the ability to test the efficacy of drugs in mouse models that show reliable, and preferably
clinically relevant, phenotypes. We previously described a number of behavioral paradigms that assess
phenotypes in the domains of motor performance, repetitive behavior, anxiety, and seizure susceptibility. Here,
we set out to evaluate the robustness of these phenotypes when tested in a standardized test battery. We
then used this behavioral test battery to assess the efficacy of minocycline and levodopa, which were
recently tested in clinical trials of AS.
Methods: We combined data of eight independent experiments involving 111 Ube3a mice and 120 wild-type
littermate control mice. Using a meta-analysis, we determined the statistical power of the subtests and the
effect of putative confounding factors, such as the effect of sex and of animal weight on rotarod performance. We
further assessed the robustness of these phenotypes by comparing Ube3a mutants in different genetic backgrounds and
by comparing the behavioral phenotypes of independently derived Ube3a-mutant lines. In addition, we investigated if
the test battery allowed re-testing the same animals, which would allow a within-subject testing design.
Results: We find that the test battery is robust across different Ube3a-mutant lines, but confirm and extend
earlier studies that several phenotypes are very sensitive to genetic background. We further found that the
audiogenic seizure susceptibility phenotype is fully reversible upon pharmacological treatment and highly
suitable for dose-finding studies. In agreement with the clinical trial results, we found that minocycline and
levodopa treatment of Ube3a mice did not show any sign of improved performance in our test battery.
Conclusions: Our study provides a useful tool for preclinical drug testing to identify treatments for Angelman
syndrome. Since the phenotypes are observed in several independently derived Ube3a lines, the test battery
can also be employed to investigate the effect of specific Ube3a mutations on these phenotypes.
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Background
Angelman syndrome (AS) is a neurodevelopmental dis-
order first described in 1965 by Harry Angelman, with a
birth incidence of approximately 1:20,000 [1]. AS is
caused by the functional loss of the maternal allele
encoding an E3 ubiquitin-protein ligase (UBE3A) [2].
Loss of functional UBE3A results in the core phenotypes
of severe intellectual disability, motor coordination defi-
cits, absence of speech, and abnormal EEG, as well as in
high comorbidity of sleep abnormalities, epilepsy, and
phenotypes related to autism spectrum [3].
Currently, only symptomatic treatments are available
for AS, primarily aimed at reducing seizures and im-
proving sleep [4]. The development of targeted treat-
ments for AS heavily relies on the ability to test the
efficacy of treatments in mouse models of the disorder.
The success of such translational studies depends on
three critical factors [5]: (1) high construct validity, (2)
high face validity, and (3) robustness of the behavioral
phenotypes. First, the construct validity (shared under-
lying etiology between mouse models and patients) of
the AS mouse model is very good, since AS mouse
models recapitulate the patient genetics by carrying a
mutated Ube3a gene specifically at the maternal allele.
However, it should be noted that the majority of the AS
patients carry a large deletion (15q11-15q13) which en-
compasses also other genes besides the UBE3A gene,
and which may contribute to a more severe phenotype
[6]. Second, with respect to face validity (i.e., similarity
of phenotypes between patient and the mouse model),
the AS mouse model captures many neurological key
features of the disorder really well (e.g., epilepsy, motor
deficits, abnormal EEG), as well as some of the behav-
ioral abnormalities (abnormal sleep patterns, increased
anxiety, repetitive behavior) [7–12]. Robustness of the
behavioral phenotypes is the third important aspect to
identify novel treatments, as it allows experiments to be
sufficiently powered to detect the effect of the treatment,
and meanwhile minimizes a type I error in which a drug
is declared effective whereas it is not. Robustness, as well
as face validity, also takes into account the sensitivity to
genetic background and the extent in which a phenotype
is also observed in independently derived mouse models.
Notably, almost all behavioral testing described in litera-
ture has been performed using the original Ube3atm1Alb
mouse strain generated in the Beaudet lab [7–9]; hence,
it is unknown to what extent the reported phenotypes
are actually specific to this mouse line.
We previously developed a series of behavioral para-
digms in the domains of motor performance, anxiety,
repetitive behavior, and seizure susceptibility, for testing
the effect of Ube3a gene reinstatement in the inducible
Ube3amSTOP/p+ (Ube3atm1Yelg) mice [13]. Here, we used
these paradigms in a highly standardized way, to assess
phenotypes in the independently derived Ube3atm1Alb
and Ube3amE113X/p+ (Ube3atm2Yelg) maternal knockout
strains. We combined data of eight independent experi-
ments across five experimenters involving 111 Ube3at-
m1Alb and 120 wild-type littermate control mice. Using a
meta-analysis, we determined the statistical power of the
different behavioral tests and the effect of putative con-
founding factors, such as the effect of sex differences.
We further assessed the robustness of these phenotypes
by comparing Ube3a mutants in different genetic back-
grounds. Finally, we employed this behavioral test bat-
tery to reassess the efficacy of minocycline and levodopa
in the AS mouse model. Minocycline is a matrix
metalloproteinase-9 inhibitor (MMP9), a tetracycline
derivative which possesses antibiotic as well as neuro-
protective activity [14, 15]. Its antibiotic properties
against both gram-positive and gram-negative bacteria
are related to its ability to bind to the bacterial 30S ribo-
somal subunit, thereby inhibiting protein synthesis [14].
Levodopa is the precursor of dopamine and was
shown to be effective in treating Parkinsonism in two
adults with Angelman syndrome [16]. Moreover, it is
able to reduce CAMK2 phosphorylation [17], which was
shown to be increased in a mouse model for Angelman
syndrome [18, 19]. Minocycline and levodopa were pre-
viously tested in the AS mouse model and based on the
favorable outcome of these preclinical experiments,
three clinical trials were performed [20–22]. Unfortu-
nately, none of these drugs showed a significant im-
provement in AS patients.
Methods
Mouse husbandry and breeding
For this study, we used Ube3am−/p+ mice (Ube3atm1Alb;
MGI 2181811) [7] and Ube3amE113X/p+ mutants (Ube3at-
m2Yelg; MGI5911277) as previously described [23].
Ube3atm1Alb mice were maintained (> 40 generations) in
the 129S2 background (full name: 129S2/SvPasCrl) by
crossing male Ube3am+/p− mice with female 129S2
wild-type mice. Ube3atm2Yelg mice were maintained (> 20
generations) in the C57BL/6J (Charles River) back-
ground by crossing male Ube3am+/pE113X mice with fe-
male C57BL/6J wild-type mice. For the seizure
susceptibility experiments with Ube3amE113X/p+ animals,
this line was backcrossed eight times in 129S2 by cross-
ing Ube3apE113X/m+ males with 129S2 wild-type females.
For behavioral experiments, female Ube3atm1Alb
(Ube3am+/p−) mice were bred to yield Ube3am−/p+ mice
in two different backgrounds: Ube3am−/p+ (AS) mice and
their WT littermates in the F1 hybrid 129S2-C57BL/6J
background (WT = 120, AS = 111) and in the 129S2
background (WT = 11, AS = 16). Ube3amE113X/p+ mice
and their WT littermates were generated in the same
manner in the F1 hybrid 129S2-C57BL/6J background
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(WT = 10, Ube3amE113X/p+ = 10) and in C57BL/6J back-
ground (WT = 15, Ube3amE113X/p+ = 16).
For the seizure susceptibility test, we used Ube3am−/p+
(WT = 45, AS = 114) and Ube3amE113X/p+ mice (WT = 4,
AS = 8) in the 129S2 background.
Mice were housed in individually ventilated cages
(IVC; 1145T cages from Techniplast) in a barrier facility.
Mice were genotyped when they were 4–7 days old and
re-genotyped at the completion of the experiments. All
animals were kept at 22 ± 2 °C with a 12-h dark and light
cycle and were tested in the light period, provided with
mouse chow (801727CRM(P) from Special Dietary Ser-
vice) and water ad libitum. During behavioral testing,
mice were group-housed with two to four animals of the
same sex per cage. Fighting between males was observed
a few times, and in these rare cases, mice were separated
and single housed. This was not a reason for exclusion.
All mice were single housed during nest building and for
the subsequent forced swim test. All animal experiments
were conducted in accordance with the European Com-
mission Council Directive 2010/63/EU (CCD approval
AVD101002016791).
Behavioral analysis
The weight of the animals was determined a few days
before the start of the behavioral analysis. Prior to each
test, mice were acclimatized to the testing room for
30 min.
All behavioral experiments were performed during
the light period of the light/dark cycle. Both male
and female mice at the age of 8–12 weeks were used
for the experiments. Moreover, we tried to obtain a
similar ratio of females/males between the WT and
AS groups. Only in the experiments described in Fig. 4
(Ube3aE113X mice in F1 background) and in the epi-
lepsy experiment using Ube3aE113X mice (Fig. 6c), the
female/male ratio between the groups was signifi-
cantly different (p < 0.05; chi-square test).
All behavioral testing and scoring was performed by
experimenters who were blind to genotype and treat-
ment. Behavioral tests were always run in the following
order and with a minimal number of days between tests:
(1) accelerating rotarod test for 5 consecutive days per-
formed at the same hour every day; (2) 2 days of pause;
(3) open field test; (4) 1 day of pause; (5) marble burying
test; (6) between 5 and 7 days of pause to allow adapta-
tion to being single caged; (7) nest building test for 5
consecutive days, in which the weight of the nest was
assessed at the same hour every day; (8) 2 days of pause;
and (9) forced swim test.
Accelerating rotarod
Motor function was tested using the accelerating rotarod
(4–40 rpm, in 5 min; model 7650, Ugo Basile Biological
Research Apparatus, Varese, Italy). Mice were given two
trials per day with a 45–60-min inter-trial interval for 5
consecutive days (same hour every day). For each day, the
average time spent on the rotarod was calculated, or the
time until the mouse made three consecutive wrapping/
passive rotations on the rotarod (latency in seconds).
These passive rotations were observed rarely (1–2%) in
129S2 or F1 hybrid 129S2-C57BL/6J mice but rather com-
mon in (30%) C57BL/6J mice. Maximum duration of a
trial was 5 min.
Open field test
To test locomotor activity and anxiety, mice were indi-
vidually placed in a 110-cm-diameter circular open field
and allowed to explore for 10 min. The light intensity
was approximately 25–30 lx measured in the center of
the arena. The total distance moved by each mouse in
the open arena was recorded by an infrared camera
(Noldus® Wageningen, NL) connected to the EthoVision®
software (Noldus® Wageningen, NL), and the final out-
come is indicated as distance moved in meters. For some
groups, we also analyzed the time spent in the inner
zone (IZ), middle zone (MZ), and outer zone (OZ) (IZ r
= 25 cm, MZ r = 40, OZ r = 55 cm).
Marble burying test
Open Makrolon (polycarbonate) cages (50 × 26 × 18 cm)
were filled with 4 cm of bedding material (Lignocel®
Hygenic Animal Bedding, JRS). On top of the bedding
material, 20 blue glass marbles were arranged in an equi-
distant 5 × 4 grid and the animals were given access to
the marbles for 30 min. After the test, the mice were
gently removed from the cage. Marbles covered for more
than 50% by bedding were scored as buried, and the out-
come measured is the number of buried marbles.
Nest building test
To measure nest building, mice were single housed for a
period of 5 to 7 days before the start of the experiment.
Subsequently, used nesting material was replaced and
11 g (11 ± 1) of compressed extra-thick blot filter paper
(Bio-rad©) was added to the cage. The amount of the
unused nest material was weighed and noted every day
for a consecutive of 5 days, each day at the same hour.
Forced swim test
Mice were placed for 6 min in a cylindrical transparent
tank (27 cm high and 18 cm diameter), filled with water
(kept at 26 ± 1 °Celsius) 15 cm deep. The mouse was
first left in the cylinder for 2 min to habituate. Immobil-
ity during the forced swim test was scored manually
(stop-watch) by timing the amount of time the mouse
was floating in the water (defined by lack of any move-
ment) and was assessed during the last 4 min of the test.
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The mouse was considered to be immobile when he
ceased to move altogether, making only movements ne-
cessary to keep its head above water. The outcome mea-
sured is the time in seconds in which the mouse was
immobile.
Susceptibility to audiogenic seizures
Because of the different genetic background require-
ments, an independent cohort of mice was used to test
susceptibility to audiogenic seizures. Mice were placed
in Makrolon (polycarbonate) cages (50 × 26 × 18 cm),
and audiogenic seizures were induced by vigorously
scraping scissors across the metal grating of the cage lid
(which creates approximately a 100-dB sound). This
noise was generated for 20 s, or less if a tonic-clonic
seizure developed before that time. Susceptible mice
responded with wild running and leaping followed by a
tonic-clonic seizure, which typically lasted 10–20 s.
Within-subject testing
For the experiment described in Fig. 3, Ube3atm1Alb mice
in F1 hybrid 129S2-C57BL/6J background were sub-
jected to the behavioral test battery for a second time.
Once the first battery was completed, female mice that
had been single housed for the nest building test were
placed back together with the original cage mates, while
male mice remained separated for the entire second set
of behavioral tasks. The second test started 4 weeks after
the first testing was completed.
Drug administration
Vehicle treatment
All animals used for the meta-analysis were treated with
vehicle either by IP injection (max volume 10 ul/g,
hypodermic-needle 25G × 16 mm (Sterican®/B-Braun)),
by oral gavage (max 10 ul/g, stainless steel animal feed-
ing tubes 20G × 38 mm (Instech Laboratories)), or by
adding to the drinking water.
Minocycline treatment
The adult-treated group consisted of 8–10-week-old
Ube3am−/p+ (n = 11 saline; 11 minocycline) and WT (n = 9
saline; 10 minocycline) littermate control mice in F1
hybrid 129S2-C57BL/6J background. Due to space limita-
tions, only six animals per group were used for nest build-
ing. Mice were assigned to two treatment groups in such a
way that both groups had a comparable distribution of
males and females and mutant and wild-type mice. Mice
were subjected to daily minocycline or vehicle IP injec-
tions (minocycline hydrochloride, Sigma-Aldrich 45 mg/
kg in saline solution), starting 3 weeks prior to commen-
cing behavioral testing, as previously described [20, 24].
Behavioral testing was started 1.5 h post-injection, based
on the half-life of minocycline (~ 2 h in plasma), and the
peak brain levels are reached about 2 h after injection
[25].
For the postnatal-treated group, cages with Ube3am−/p
+ and WT pups in F1 hybrid 129S2-C57BL/6J back-
ground were split in two treatment groups in such a way
that both groups had a comparable distribution of males
and females and mutant and wild-type mice. The treat-
ment group received minocycline via the lactating dam,
which received minocycline through the drinking water
(0.2 mg minocycline/ml, supplemented with 1 mg/ml
aspartame to counteract the bitter taste and shielded for
light) [26]. This method of administration was shown to
yield detectable concentration of minocycline in the
blood of adult mice [27] and in the breast milk of lactat-
ing dams [28, 29]. Once the mice were weaned, they
were supplied with the same concentration of minocy-
cline in their drinking water. Assuming a water intake of
1.5 ml/10 g body weight/day [30], and assuming an aver-
age weight of 25 g/mouse, the average amount of mino-
cycline these mice received is approximately 30 mg/kg/
day. The drinking water was refreshed every other day.
Treatment continued until all behavioral experiments
were completed. The control group received water with
aspartame.
Levodopa/carbidopa treatment
Cages containing Ube3am−/p+ and wild-type littermate con-
trol mice (8–12 weeks old) in the F1 hybrid 129S2-C57BL/
6J background were assigned to two treatment groups in
such a way that both groups had 15 wild type and 15 mu-
tants and a comparable distribution of males and females.
Mice in the treatment group received 15 mg/kg levodopa
and 3.75 mg/kg carbidopa dissolved in saline (levodopa,
Sigma-Aldrich; carbidopa, Sigma-Aldrich) by IP injection
with an injection volume of 10 ul/g. The untreated group
received vehicle injection by IP as described by Tan et al.
[21]. The mice were injected 1 h prior to carrying out the
behavioral tasks, during the entire period while partaking in
these tests.
Levetiracetam treatment
Ube3am−/p+ mice in the 129S2 background were first
tested for audiogenic seizure susceptibility at baseline.
Minimally 24 h later, the mice were again tested for
audiogenic seizure susceptibility, this time precisely 1 h
following a single IP injection of levetiracetam (0–0.5–
1–2–10–15 mg/kg; Sigma-Aldrich). The injection vol-
ume used is 5 ml/kg, and the drug was dissolved in 1%
Tween-80 (Sigma-Aldrich) in milliQ water as previously
described [31].
Data analysis
Data was analyzed using Excel 2010 (Microsoft) and
IBM SPSS software (NY, USA). The open field, marble
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burying, and forced swim test data were analyzed using
an unpaired T test in the untreated experimental groups
and a two-way ANOVA in minocycline- and
levodopa-treated animals (in which we assessed a
genotype-treatment interaction). Rotarod and nest build-
ing were measured with a repeated measures ANOVA in
the untreated experimental groups, or with a multivari-
ate repeated measures ANOVA (assessing significance of
interaction of time, genotype, and treatment) in the min-
ocycline and levodopa experimental groups. We used a
Bonferroni’s post hoc test to detect significant differences
in male and female groups. For the within-subject ex-
periment, we used a paired T test for open field, marble
burying, and forced swim tests, while we used a repeated
measures factorial ANOVA when analyzing the rotarod
and the nest building test. For the audiogenic seizure
analysis, a Fisher’s exact test was used. The correlation
between body weight and maximal performance on the
rotarod test was assessed with a Pearson’s correlation
test. For the power calculation, we performed a priori
analysis using G*Power 3.1 software [32] with α = 0.05
and power (1 − β) = 0.95, 0.90, or 0.80. Data is presented
as mean± SEM in all figures. For all tests, statistical sig-
nificance was denoted by p ≤ 0.05 (*), p < 0.01 (**), and
p < 0.001 (***).
A chi-square test was performed to test if there were
any significant differences in the ratio of females/males
between the WT and AS groups.
Results
Robust behavioral phenotypes in Ube3am−/p+ mice in the
F1 hybrid 129S2-C57BL/6J background
We recently developed a number of behavioral tests
for testing the effect of gene reinstatement in indu-
cible Ube3amSTOP/p+ (Ube3atm1Yelg) mice [13]. These
tests can be applied in successive order to assess phe-
notypes in the domains of motor performance, anx-
iety, and repetitive behavior. Here, we set out to
assess the robustness of these phenotypes in an inde-
pendently derived mouse model of AS, by using F1
hybrid 129S2-C57BL/6J Ube3am−/p+ (Ube3atm1Alb)
mice [7], which is the Ube3a mouse mutant used for
nearly all behavioral studies. We have frequently used
this strain to test the efficacy of novel treatments and
combined all data obtained from vehicle-treated
Ube3am−/p+ and wild-type littermate controls in the
F1 hybrid 129S2-C57BL/6J background to perform a
meta-analysis. In total, this constitutes the combined
data of eight experiments, carried out by five experi-
menters and totaling 111 Ube3am−/p+ and 120
wild-type littermate controls (Table 1; Fig. 1).
Individuals with Angelman syndrome show clear
motor impairments, and impaired performance on the
accelerating rotarod is the most frequently described
phenotype in Ube3a mice. Indeed, our meta-analysis
shows a very robust significant difference between the
two genotypes (p < 0.001; Fig. 1a). A power analysis with
Table 1 Overview of experiments used for the meta-analysis
Exp. # Person WT/MUT (n) Sex
WT f/m
MUT f/m
(n)
Rotarod
(time(s))
WT mean (SD)
Mut mean (SD)
Open field
(distance(m))
WT mean (SD)
Mut mean (SD)
Marble burying
(# marbles buried)
WT mean (SD)
Mut mean (SD)
Nest building
(% material used)
WT mean (SD)
Mut mean (SD)
Forced swim test
(% floating)
WT mean (SD)
Mut mean (SD)
1 A 15/13 8/7
6/7
128 (42)
96 (32)
41 (14)
22 (11)
11 (4)
4 (3)
14 (25)
79 (18)
53 (23)
83 (7)
2 A 15/13 5/10
3/10
142 (43)
80 (32)
49 (10)
32 (12)
8 (4)
2 (3)
36 (23)
79 (14)
44 (24)
81 (7)
3 A 15/13 5/10
3/10
133 (42)
92 (46)
40 (12)
29 (8)
11 (3)
2 (2)
27 (18)
70 (18)
41 (19)
73 (14)
4 B 21/171) 10/11
7/10
159 (60)
102 (36)
31 (12)
19 (11)
14(4)
4(5)
10 (11)
48 (25)
24 (22)
63 (18)
5 C 9/112) 5/4
6/5
163 (49)
91 (37)
25 (6)
10 (7)
12 (5)
4(5)
48 (27)
69 (12)
28 (24)
76 (8)
6 D 15/143) 4/11
6/8
107 (44)
74 (26)
44 (7)
29 (13)
12 (3)
3 (3)
40 (18)
79 (12)
14 (20)
60(31)
7 E 15/15 8/7
7/8
196 (57)
126(52)
45(10)
35 (7)
11 (5)
6 (3)
63 (20)
74 (14)
47 (20)
67 (14)
8 A 15/154) 7/8
8/7
162 (49)
95 (35)
49 (9)
33 (13)
10 (3)
2 (3)
N/A 47 (20)
88 (9)
All experiments were performed using Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. For all tests shown in this table, we found a significant effect of
genotype (p < 0.05), except for the nest building test of experiment 8, which was not performed. The table indicates the individual that performed the test
battery, the number of wild-type and mutant mice used for each test, the number of females and males used for each experimental group, and the mean and
standard deviation of the outcomes obtained. For the rotarod, we indicated the average performance over the 5 days, while for the nest building we provided the
data as measured at day 5. Note that for some of the tests, we used a different number of mice (mice were not properly tracked, or a smaller cohort was used for
nest building because of space limitations). The adapted n for these experiments is as follows: 1)nest building 13/12, forced swim test 20/17; 2)nest building 6/7;
3)open field 13/14; 4)open field 10/10, nest building not performed
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Fig. 1 (See legend on next page.)
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α = 0.05; (1 − β) = 0.95 showed that this task requires 14
animals per genotype (Table 2).
Following 2 days of rest, the same mice were then
tested in the open field test. This paradigm is com-
monly used to assess anxiety in mice. Increased anx-
iety is commonly observed in individuals with AS
[33], as well as individuals with autism spectrum dis-
order. In this test, we place the mice in an open
arena situated in a brightly lit room and record the
distance the mice travel during a 10-min time span.
The measurements of the distance moved in the open
arena indicated that AS mice moved significantly less
(WT 40.3 ± 1.2 m; AS 26.2 ± 1.2 m; p < 0.001;
Fig. 1b). A power analysis (α = 0.05; (1 − β) = 0.95)
showed that this task requires a minimum number of
21 mice per genotype, which makes this test a relative
weak test (Table 2). Previous studies reported no
significant difference observed between genotypes in
the time spent in the [8, 9] inner zone of the open
field, which is another measure of anxiety. Our
meta-analysis revealed a significant difference between
genotypes (p < 0.005), but this difference was small
(WT 1.1% versus mutant 0.7% time in inner zone),
and a significant effect was only observed in four out
of the eight individual experiments (data not shown).
After 1 day of rest, the same mice were then analyzed
in the marble burying test, a test used to assess repetitive
and perseverative behavior as well as anxiety [34, 35].
When exposed to marbles, AS mice show a strongly im-
paired marble burying behavior compared to WT mice
(WT 11.3 ± 0.4; AS 3.6 ± 0.3; p < 0.001; Fig. 1c). A power
analysis (α = 0.05; (1 − β) = 0.95) showed that seven ani-
mals/group are sufficient for this test, indicating a very
robust phenotype (Table 2).
After the marble burying task, all mice were single
housed for 5–7 days and then analyzed for 5 consecutive
days while performing the nest building test. The nest
building test assesses the innate behavior of mice to create
a nest to maintain body temperature and to find shelter
[36]. AS mice showed a clear phenotype compared to their
WT control littermates (p < 0.001; Fig. 1d). As indicated in
Table 2, the nest building phenotype is quite robust, since
it only requires 8 mice (α = 0.05; (1 − β) = 0.95) per group
if analyzed over the last day.
Following 2 days of pause, the animals were finally
subjected to the forced swim test, in which the mouse is
placed in a beaker filled with water, from which the
mouse will try to escape by swimming. This test is typic-
ally used to test depressive-like behavior in mice [37].
AS mice showed significant more time floating (instead
(See figure on previous page.)
Fig. 1 Behavioral testing of Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. For each behavioral paradigm, the pooled (raw) data of all
experiments is presented on the left panel, whereas the Forrest plots in the middle panel show the normalized data of the individual experiments (in
which the data of each experiment is normalized against wild type; represented by a dashed line), as well as the 95% confidence interval. The picture
on the right panel shows the behavioral set-up used for our experiments. For the marble burying test and nest building test, the picture shows the
onset and finish of a behavioral experiment. a Accelerating rotarod in wild-type (WT) and Ube3am−/p+ mice (n = 120, 111). b Open field test in WT and
Ube3am−/p+ mice (n = 113, 106). c Marble burying test in WT and Ube3am−/p+ mice (n = 120, 111). d Nest building test in WT and Ube3am−/p+ mice
(n = 94, 86). e Forced swim test in WT and Ube3am−/p+ mice (n = 120, 111). All data represent mean ± SEM. A repeated measures ANOVA or T test was
used for statistical comparison of the non-normalized data. All tests show a significance effect of genotype (***p < 0.001)
Table 2 Achieved power for each behavioral test of the behavioral test battery
Wild type
(mean ± SD)
Ube3a
(mean ± SD)
Test Achieved
effect size
Sample size per
group
(1-β)= 0.95
Sample size per
group
(1-β) = 0.90
Sample size per
group
(1-β) = 0.80
Rotarod
Time on machine (s)
149 ± 55 95 ± 40 ANOVA 0.56 14 11 9
Open field
Distance moved (m)
40 ± 13 26 ± 13 T test 1.17 21 17 13
Marble burying
(# marbles buried)
11 ± 4 4 ± 4 T test 2.26 7 6 5
Nest building
(% used nesting material)
68 ± 23 28 ± 19 T test 1.95 8 7 6
Forced swim test
(% floating time)
37 ± 25 73 ± 18 T test 1.73 10 9 7
Susceptibility to audiogenic seizure
(% of animals)
7 98 T test 4.55 3 3 3
Data provided is based on the experiments using Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. The table provides the obtained effect size, number
of mice needed per genotype for each behavioral test (with power equal to 0.95, 0.90, 0.80), and statistical test used. For rotarod calculations, we used the
average performance over the 5 days, while for the nest building we used the data of the last test day
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of swimming) compared to WT mice (WT 36.8 ± 2.3;
AS 72.6 ± 1.7; p < 0.001; Fig. 1e). The power analysis
test showed that this task requires a minimum of 10
mice (α = 0.05; (1 − β) = 0.95).
Taken together, the data indicates that this test battery
yields a series of robust behavioral phenotypes that can
be obtained in a relative quick manner using a single
cohort of mice.
The dependence of sex on the behavioral phenotypes
Angelman syndrome affects both males and females,
with no known differences between the sexes. To assess
if this is also the case for the Ube3a mouse phenotypes
described above, we analyzed if there were any signifi-
cant sex differences. An effect of sex was noted on the
rotarod, in which female wild-type and Ube3a mice per-
formed significantly better than male wild-type and
Ube3a mice (p < 0.001; Fig. 2a). Since male mice are
heavier than female mice and since Ube3am−/p+ mutants
show increased weight (Fig. 2f ) [8, 38], we investigated if
the impaired rotarod performance as seen in Ube3am−/p
+ mutants could be attributed to their increased weight.
Hence, we performed a correlation analysis between
body weight and time on the rotarod (as measured on
the last training day). As shown in Fig. 2g, no meaning-
ful correlation is observed between body weight and
latency to fall in both WT mice and AS mice (WT males
Pearson r = 0.08, AS males Pearson r = − 0.21, WT
females Pearson r = 0.35, AS females Pearson r = 0.02),
although the correlation observed in WT female mice
was just statistically significant (p < 0.05), indicating that
increased bodyweight actually improves (rather than im-
pairs) rotarod performance. Overall, we conclude that
the impaired motor performance of Ube3am−/p+ mutants
on the rotarod is not caused by the increased body
weight observed in these mice, but truly reflects differ-
ences in motor performance.
We also observed a small effect of sex for the nest
building task in which female Ube3am−/p+ mutants out-
performed the male Ube3am−/p+ mutants (p < 0.05). A
similar tendency was also observed in wild-type mice,
but this effect was not significant (Fig. 2b). Despite the
slightly better performance of female Ube3am−/p+ mu-
tants, female Ube3am−/p+ mutants were still significantly
different from wild-type mice (p < 0.001).
We observed no significant effect of sex in the open
field test (p = 0.25), marble burying test (p = 0.06), and
forced swim test (p = 0.27; Fig. 2c–e). Overall, these data
suggest that the set of behavioral phenotypes observed
in AS mice are robust and are not markedly influenced
by the sex of the animal. However, given the decreased
performance of male mice on the rotarod, mixed cohorts
used for rotarod testing should be well balanced with re-
spect to sex to obtain a reliable phenotype.
The behavioral test battery is suitable for within-subject
testing design
A within-subject testing design is a powerful design for
drug testing purposes, as it allows assessing the efficacy
of a drug with considerable fewer animals. Therefore, we
investigated whether the behavioral test battery allowed
re-testing the same animals while maintaining a similar
phenotype, which is a prerequisite for applying a
within-subject design. We subjected 15 Ube3am−/p+ mice
(Ube3atm1Alb) and 15 WT littermates in the F1 hybrid
129S2-C57BL/6 background to the behavioral test bat-
tery and repeated the test battery after a pause of
4 weeks. As shown in Fig. 3, performance on the rotarod
test, nest building test, and forced swim test was highly
similar when the initial test data were compared to the
re-testing data. However, performance in the open field
test as well as marble burying test was significantly dif-
ferent when this test was performed for the second time
(open field: wild type initial vs retest p < 0.001, Ube3am
−/p+ initial vs retest p < 0.001; marble burying: wild type
initial vs retest p < 0.001, Ube3am−/p+ initial vs retest p <
0.001; paired T test). These differences upon re-testing
are likely due to the decreased anxiety levels and or
habituation of the mice upon re-testing in these para-
digms. Importantly, Ube3am−/p+ mice remained sig-
nificantly different from wild-type littermates when
tested for a second time, with the exception of the
marble burying test, which no longer yielded a
phenotype upon re-testing (p = 0.13). Hence, we con-
clude that most tests of the behavioral test battery
are suitable for a within-subject design to test the ef-
ficacy of a drug.
Behavioral phenotypes are also observed in the
Ube3aE113X mouse model
The results above indicate that the behavioral test battery
gives robust phenotypes in the Ube3atm1Alb line as well as
in the previously published Ube3amSTOP/p+ (Ube3atm1Yelg)
line. In order to test the robustness of the battery in a third
independently derived Ube3a-mutant strain, we used the
Ube3amE113X/p+ (Ube3atm2Yelg) strain, which we recently
described [23]. As shown in Fig. 4, the Ube3amE113X/p+-mu-
tant mice in the F1 129S2-C57BL/6J background showed
again clear impairments on the rotarod test (p < 0.001),
open field test (p < 0.001), marble burying test (p < 0.05),
nest building test (p < 0.01), and forced swim test (p <
0.001). Taken together, these data suggest that the identified
set of behavioral phenotypes in this test battery is present
in three independently derived Ube3a-mutant lines.
Mouse genetic background affects the identified AS
phenotypes
Previous studies have indicated the importance of the
genetic background for certain Ube3a phenotypes [8, 9].
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To test the importance of the genetic background on the
behavioral test battery, we performed the test battery on
AS mice on a pure C57BL/6J (Fig. 4) and 129S2 back-
ground (Fig. 5) instead of the F1 hybrid background.
Ube3amE113X/p+ mice in C57BL/6J background showed a
similar phenotype as Ube3amE113X/p+ mutants in the F1
hybrid 129S2-C57BL/6J background with respect to the
rotarod test (p < 0.01), marble burying test (p < 0.001),
Fig. 2 Effect of sex on the behavioral phenotypes of Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. a Accelerating rotarod in WT and Ube3am
−/p+ female mice (n= 52, 46) and in WT and Ube3am−/p+ male mice (n= 68, 65). b Nest building test in WT and Ube3am−/p+ female mice (n= 42, 33) and in
WT and Ube3am−/p+ male mice (n= 52, 53). c Open field test in WT and Ube3am−/p+ female mice (n= 47, 41) and in WT and Ube3am−/p+ male mice (n= 66,
65). d Marble burying test in WT and Ube3am−/p+ female mice (n= 52, 46) and in WT and Ube3am−/p+ male mice (n= 68, 65). e Forced swim test in WT
and Ube3am−/p+ female mice (n= 52, 46) and in WT and Ube3am−/p+ male mice (n= 68, 65). f Bodyweight in WT and Ube3am−/p+ female mice (n= 37, 33)
and in WT and Ube3am−/p+ male mice (n= 53, 50). g Pearson correlation test between body weight and latency to fall at day 5 in WT and Ube3am−/p+
female mice (n= 37, 33) and in WT and Ube3am−/p+ male mice (n= 53, 50). Multivariate repeated ANOVA or a two-way ANOVA was used for statistical
comparison. A Bonferroni’s post hoc test was used to detect significant differences in behavioral phenotypes of male and female groups. All data represent
mean ± SEM. Significant effects of genotype or sex are indicated as *p< 0.05, **p< 0.01, and ***p< 0.001
Sonzogni et al. Molecular Autism  (2018) 9:47 Page 9 of 19
and nest building test (p < 0.001) (Fig. 4). No deficit was
observed in the open field test (p = 0.75). Notably, the
Ube3amE113X/p+ mice in C57BL/6J background showed a
significant phenotype in the forced swim test (p < 0.05),
however in the opposite direction compared to AS mice
in F1 hybrid 129S2-C57BL/6J background.
The test battery was also performed using Ube3atm1Alb
mice in the inbred 129S2 background (Fig. 5).
Ube3atm1Alb mice in the 129S2 background did not show
any of the phenotypes observed in Ube3atm1Alb mice in
the F1 hybrid background, with the exception of the
forced swim test (p < 0.05), which yielded a similar result
as obtained in mice in the F1 hybrid background. Taken
together, these data confirm and extend previous studies
that most AS mouse phenotypes are strongly dependent
on the genetic background.
Fig. 3 Most behavioral phenotypes are stable upon re-testing Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. a, c, e–g WT and Ube3am−/p
+ mice at initial testing and b, d, e–g upon re-testing. A single cohort of 15 wild-type (8 females, 7 males) and 15 Ube3atm1Alb (8 females, 7 males) mice
was used for all experiments. A repeated measures ANOVA or T test was used for statistical comparison of genotypes, as described in the legend of
Fig. 1. All data represent mean ± SEM. Significant effects of genotype are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001 for genotype significance
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Susceptibility to audiogenic seizures
Epilepsy is a common feature of individuals with AS
[39]. We previously showed that Ube3atm1Alb mice as
well as Ube3amSTOP/p+ (Ube3atm1Yelg) mice are highly
susceptible to audiogenic seizures, a phenotype that is
specifically observed in mice in the 129S2 background
[7]. To investigate the strength of this test in more de-
tail, we performed a meta-analysis of five independent
experiments with a total of 114 Ube3am−/p+ (Ube3at-
m1Alb) mice and 45 wild-type littermates in the 129S2
Fig. 4 Behavioral testing of Ube3amE113X/p+ (Ube3atm2Yelg) mice in the F1 hybrid 129S2-C57BL/6J and the C57BL/6J background. a, b Accelerating
rotarod in WT and Ube3amE113X/p+ mice in F1 hybrid 129S2-C57BL/6J and C57BL/6J background. c, d Nest building test in WT and Ube3amE113X/p+
mice in F1 hybrid 129S2-C57BL/6J and C57BL/6J background. e–g Open field, marble burying, and forced swim tests in WT and Ube3amE113X/p+
mice in F1 hybrid 129S2-C57BL/6J and C57BL/6J background. For all behavioral tests, we used a single cohort of 10 wild-type (1 female, 9 males)
and 10 Ube3amE113X/p+ mice (6 females, 4 males) in F1 hybrid 129S2-C57BL/6J, and 15 wild-type (11 females, 4 males) and 16 Ube3amE113X/p+
(Ube3atm2Yelg) (13 females, 4 males) mice in C57BL/6J background. All data represent mean ± SEM. A repeated measures ANOVA or T test was
used for statistical comparison of genotypes, as described in the legend of Fig. 1. Significant effects of genotype are indicated as *p < 0.05, **p < 0.01,
and ***p < 0.001
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Fig. 5 Behavioral testing of Ube3am−/p+ (Ube3atm1Alb) mice in the 129S2/SvPasCrl background. a–e Accelerating rotarod, nest building, open field,
marble burying, and forced swim test in wild-type and Ube3atm1Alb mice in 129S2/SvPasCrl background (n = 11, 16) (WT = 5 females, 6 males)
(Ube3am−/p+ = 8 females, 8 males). A repeated measures ANOVA or T test was used for statistical comparison of genotypes, as described in the
legend of Fig. 1. Significant effects of genotype are indicated as *p < 0.05
Fig. 6 Audiogenic seizure susceptibility of Ube3am−/p+ and Ube3amE113X/p+ mice in the 129S2/SvPasCrl background. a Audiogenic seizure susceptibility
of WT and Ube3am−/p+ mice (n = 45, 114). b Effect of sex on seizure susceptibility in wild-type and Ube3am−/p+ mice (females n = 24, 62; males n = 21,
52). c Seizure susceptibility in wild-type and Ube3amE113X/p+ mice (n = 4, 8) (WT = 3 females, 1 males; Ube3amE113X/p+ = 1 females, 7 males). d Effect of
increasing doses of levetiracetam on epilepsy susceptibility of Ube3am−/p+ mice (0 mg/kg, n = 12; 0.5 mg/kg, n = 6; 1 mg/kg, n = 6; 2 mg/kg, n = 30;
5 mg/kg, n = 30; 15 mg/kg, n = 30). Fisher’s exact test was used for statistical comparison. ***p < 0.001 for genotype significance
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background. This analysis showed that this is a very ro-
bust phenotype with seizures observed in 98% of
Ube3am−/p+ mice and in 7% of the wild-type littermates
(p < 0.001). The robustness of this test was further con-
firmed by a power calculation analysis (Table 2).
We tested whether seizures were also present in the
Ube3amE113X/p+ (Ube3atm2Yelg) line. To that end, we
crossed Ube3apE113X/m+ females (backcrossed eight times
in 129S2) with 129S2 males. As shown in Fig. 6, an au-
diogenic seizure could be provoked in all Ube3amE113X/p
+ mutants tested (p < 0.001), indicating that this pheno-
type is observed across three independently derived
Ube3a-mutant lines.
We previously demonstrated that the sensitivity to
audiogenic seizures can be reversed upon acute treat-
ment with anti-epileptic drugs [13]. Given the high
power of this assay, we investigated if this assay is suit-
able to determine the effective dose of a treatment. To
that end, we treated mice with levetiracetam, a com-
pound that acts as ligand of the synaptic vesicle protein
2A, which is a commonly used anti-epileptic drug for
both partial and generalized seizures and which is also
often prescribed to individuals with AS [40, 41]. Ube3am
−/p+ (Ube3atm1Alb) mice in 129S2 background were first
assessed for their (baseline) sensitivity to audiogenically
evoked seizures without treatment. After establishing
that all mice were sensitive, mice received at least 1 day
after baseline testing a single IP dose of levetiracetam
and were tested 1 h after IP injection. As shown in
Fig. 6d, a good dose-response curve could be obtained,
in which 2 mg/kg levetiracetam yielded approximately
60% of mice to be resistant to audiogenic seizures. This
indicates that this test is highly suitable for quickly
determining the effective dose of a treatment.
Minocycline treatment does not improve behavioral
phenotypes of Ube3a mice
It has previously been reported that minocycline
treatment of Ube3a animals improves synaptic plasti-
city as well as motor coordination, which was the
basis for an open-label study with minocycline in in-
dividuals with AS (trial register NCT01531582 and
[20]), as well as a randomized controlled trial
((NCT02056665), [22]). Unfortunately, the randomized
trial showed no difference between placebo and
minocycline-treated individuals [22]. To test if mino-
cycline ameliorated the Ube3a-mutant phenotypes in
our behavioral test battery, we subjected the animals
to the same treatment protocol as used for the initial
mouse study [20]. Adult-treated Ube3am−/p+ (Ube3at-
m1Alb) mice and littermate controls (8–12 weeks of
age) in the F1 hybrid 129S2-C57BL/6J background re-
ceived daily minocycline (45 mg/kg) or control saline
IP injections starting 3 weeks prior to behavioral
testing. After 3 weeks of daily injections, the mice
were sequentially subjected to the behavioral test bat-
tery as described above. In contrast to the previous
finding (trial register NCT01531582), we did not
observe a rescue on the rotarod. We also observed
no effect of minocycline on any of the other tests of
the behavioral battery (Fig. 7; two-way ANOVA, geno-
type/treatment interaction p > 0.08 in all tests).
Notably, prolonged exposure to daily minocycline in-
jections resulted in yellow deposits over the organs
and dullness of the liver (data not shown), confirming
previous studies that IP administration of minocycline
is not the best choice of administration [42].
Minocycline has also been used to reverse the be-
havioral deficits of a mouse model of Fragile X [26,
43]. Notably, in these studies, minocycline treatment
was initiated immediately after birth and provided
though the drinking water. Since we previously
showed that a behavioral rescue of Ube3a mice may
also depend on the timing of treatment initiation
[13], we decided to treat Ube3a animals immediately
after birth, using the same protocol as described for
FMRP mice [26]. However, also this prolonged post-
natal treatment regimen did not yield a significant be-
havioral improvement, as none of these tests showed
a significant interaction of genotype and treatment
(two-way ANOVA, genotype/treatment interaction p >
0.16 in all tests) (Fig. 7).
Levodopa/carbidopa treatment does not improve
behavioral phenotypes of Ube3a mice
A recent study showed that treatment of Ube3a mice
with levodopa resulted in improvement of their motor
skills compared to untreated Ube3a mice [21]. Based on
this preclinical observation, a placebo-controlled trial of
levodopa was initiated in 55 children between 4 and
12 years diagnosed with AS. Unfortunately, no signifi-
cant improvement was observed on any of the outcomes
measured following a 1-year treatment (trial register
NCT01281475 and [21]). To test as to what extent levo-
dopa ameliorated the phenotypes of Ube3am−/p+
(Ube3atm1Alb) mice in our behavioral battery, we sub-
jected the animals to the same treatment protocol as
used for the initial mouse study [21]. Ube3am−/p+ and
wild-type littermates (8–12 weeks of age) in F1 hybrid
129S2-C57BL/6J background received daily levodopa/
carbidopa (15 mg/kg levodopa and 3.75 mg/kg carbi-
dopa) or control saline IP injections, starting 1 h prior
to behavioral testing. In contrast to the earlier finding
[21], we did not observe a rescue on the rotarod. We
also observed no effect of levodopa treatment on any of
the other tests of the behavioral battery (two-way
ANOVA, genotype/treatment interaction p > 0.17 in all
tests) (Fig. 8).
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Fig. 7 Effect of minocycline treatment on adult and young Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. a Timeline representing
minocycline treatment and behavioral phenotyping of adult Ube3am−/p+ mice. b–f Effect of minocycline on adult Ube3atm1Alb mice on the behavioral test
battery. Wild-type and Ube3am−/p+ (Ube3atm1Alb) vehicle-treated adult mice: n= 9, 11 (WT= 5 females, 4 males; Ube3am−/p+= 6 females, 5 males), with the
exception of the nest building (n= 6, 7). Minocycline-treated wild-type and Ube3am−/p+ (Ube3atm1Alb) adult mice: n= 10, 11 mice (WT= 6 females, 4 males;
Ube3am−/p+= 6 females, 5 males), with the exception of the nest building (n= 6, 6). g Timeline representing minocycline treatment and behavioral
phenotyping of young Ube3am−/p+ mice. h–l Effect of minocycline on young Ube3atm1Alb mice on the behavioral test battery. Wild-type and Ube3am−/p+
(Ube3atm1Alb) vehicle-treated young mice: n= 21, 17 (WT= 11 females, 10 males; Ube3am−/p+= 7 females, 10 males), with the exception of the nest building
(n= 13, 12) and the forced swim test (20, 17). Minocycline-treated wild-type and Ube3am−/p+ (Ube3atm1Alb) young mice: n= 33, 22 mice (WT = 20 females, 13
males; Ube3am−/p+= 8 females, 14 males), with the exception of the open field (33, 21), the marble burying (33, 21), and the nest building (n= 16, 17). A
multivariate repeated ANOVA or a two-way ANOVA was used for statistical comparison in behavioral phenotypes. *p< 0.05 and ***p< 0.001 indicate the
effect of genotype. In none of the tests, we observed an interaction of genotype and treatment
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Discussion
Robust behavioral phenotypes with high construct and
face validity in mouse models of disease are critical for
the identification of novel treatments and the successful
translation of these therapies to clinical trials. These pre-
clinical studies may give us important information about
the therapeutic dose, optimal age of treatment, and the
best outcome measures to be used in a clinical trial.
Given the high failure rate of clinical trials aimed at im-
proving cognitive function [44], it is absolutely critical
that the preclinical data is robust (reproducible results
across different mutant lines and different experi-
menters) and that the animal studies have high construct
and face validity.
In this study, we investigated the robustness of a num-
ber of behavioral phenotypes, which we previously de-
scribed using the inducible Ube3amSTOP/p+ (Ube3atm1Yelg)
mice [13]. These phenotypes were assessed in two inde-
pendently derived Ube3a lines: in the commonly used
Ube3atm1Alb line [7] and the recently generated Ube3a-
mE113X/p+ (Ube3atm2Yelg) line [13]. Recently, we have tested
two additional novel Ube3a lines in this test battery with
Fig. 8 Effect of levodopa treatment on Ube3atm1Alb mice in F1 hybrid 129S2-C57BL/6J background. a Timeline representing levodopa treatment
and behavioral phenotyping of Ube3am−/p+ mice. b–f Effect of levodopa on the behavioral test battery. Wild-type and Ube3am−/p+ (Ube3atm1Alb)
vehicle-treated mice: n = 15, 15 (WT vehicle = 8 females, 7 males; Ube3am−/p+ vehicle = 7 females, 8 males), levodopa-treated wild-type and Ube3am−/p+
(Ube3atm1Alb) mice: n = 15, 15 mice (WT levodopa = 8 females, 7 males; Ube3am−/p+ levodopa = 6 females, 9 males). A multivariate repeated ANOVA or
a two-way ANOVA was used for statistical comparison in behavioral phenotypes. ***significant effect of genotype p < 0.001. No effect of genotype was
observed in the open field test, since levodopa-treated wild-type mice were similar to Ube3a mice. In none of the tests, we observed an interaction of
genotype and treatment
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the same results; the Ube3atm1.1Bdph line (MGI:5882092)
and a novel (unpublished) Ube3a line (Ube3aem1Yelg).
Thus, taken together, a total of five independently derived
Ube3a lines show phenotypes on all the behavioral tests of
the test battery described in this study. In all cases, we
used heterozygous Ube3a mice in which the mutation was
located on the maternally inherited Ube3a allele. There-
fore, we conclude that construct validity is very high.
However, since the majority of individuals with AS carries
a large chromosomal deletion of the AS critical region
(15q11-q13) which encompasses also other genes besides
Ube3a and which may contribute to a more severe pheno-
type [6], it would be of interest to test a mouse model of
AS with large maternal deletion [11] in our behavioral test
battery.
In terms of face validity, we used behavioral para-
digms that assess domains of motor performance,
anxiety, repetitive behavior, and seizure susceptibility,
which are all relevant clinical phenotypes of AS.
Nevertheless, the clinical translational value of some
of our tests (e.g., open field, marble burying, nest
building, and forced swim tests) may be limited. Al-
though it is notable that many of our tests involve a
strong motor component, we think that it is unlikely
that the phenotypes observed in the open field, mar-
ble burying, nest building, and forced swim tests are
solely related to deficits in the domain of motor func-
tioning. Most notably, we have shown that the critical
period for rescuing these phenotypes is distinctly dif-
ferent compared to rescuing the rotarod deficit [13]
(and unpublished data). For instance, we found that
gene reactivation in 3-week-old mice fully rescues the
rotarod phenotype, but none of the other phenotypes
[13]. It is further noticeable that both WT and mu-
tant mice behave significantly different when tested
for a second time in the open field and marble bury-
ing tests, whereas no significant changes were
observed in rotarod performance. This further indi-
cates that the deficits in the open field and marble
burying tests are indicative of deficits in other do-
mains than motor performance.
An important clinical feature of AS that is lacking in
our behavioral test battery is a paradigm that assesses
cognitive function. Despite profound cognitive impair-
ments in individuals with AS, learning deficits in the AS
mouse model are rather mild. We and others have
reported learning deficits in AS mice by using the
Morris water maze [8, 18, 45]. However, this paradigm is
very labor intensive and hence less suitable for drug test-
ing. Moreover, we found that a large number of mice are
needed to detect significant differences and results var-
ied strongly among experimenters (data not shown). A
good learning paradigm that is highly suitable for drug
testing is fear conditioning, in which animals are
subjected to a single training session in which they are
trained to associate a context (training chamber) or cue
(tone) with a foot shock. However, we have not been
able to get consistent results across experiments and
experimenters (data not shown), and varying results are
published in literature, with some studies showing a spe-
cific deficit in context conditioning [7, 46] and others a
specific deficit in cued conditioning [8] or both [47–49].
Notably, the two studies that investigated the behavioral
deficits of Ube3a mice across strains in great detail
showed no context conditioning deficit in Ube3a mice
in the F1 hybrid 129-C57BL/6J background and C57BL/
6J background, and either normal [9] or impaired [8]
cued fear conditioning in Ube3a mice in the C57BL/6J
background. Collectively, these studies indicate that this
phenotype is rather weak, and hence results, obtained
with these tests should be interpreted with care.
By combining the data of eight independent experi-
ments performed by five different experimenters, we
were able to perform a meta-analysis of 111 Ube3am−/p+
(Ube3atm1Alb) and 120 WT littermate mice in the F1 hy-
brid 129S2-C57BL/6J background and determine the ro-
bustness of the phenotypes. In all eight experiments, we
replicated Ube3a phenotypes observed on the rotarod
test, open field test, marble burying test, nest building
test, and the forced swim test. Deficits of Ube3a mice in
rotarod performance, open field behavior, and marble
burying have been reported by many other investigators,
and hence, our results confirm the robustness of these
tests. Impaired nest building behavior and impaired per-
formance in the forced swim test of Ube3a mice have
not yet been reported by other laboratories, but our
study shows that these deficits are also very robust. In
fact, a power analysis showed that these tests are among
the most robust tests of the behavioral test battery. The
open field paradigm was found to have the weakest
power.
Our meta-analysis further shows that there is no major
effect of sex on the behavioral phenotypes, which is in
line with the general notion that such differences are
also not present in AS patients. We did however find
that female wild-type and mutant mice outperformed
male wild-type and mutant mice on the rotarod. Im-
proved performance of female mice on the rotarod has
also been reported previously [50] and emphasizes the
need of using well-matched groups when groups of both
sexes of Ube3a mice are tested on the rotarod. Given
that male mice are heavier than female mice, we investi-
gated if the impaired performance of Ube3a mice on the
rotarod can be attributed to the increased weight of
these mutants. However, we found no correlation be-
tween weight of the animal and performance on the
rotarod. This observation is in line with other studies
[50–52] and indicates that the reduced performance of
Sonzogni et al. Molecular Autism  (2018) 9:47 Page 16 of 19
Ube3a mice on the rotarod represents a bona fide im-
pairment in motor performance.
Besides the reproducibility of the observed phenotypes
and the high face and construct validity, there are two
additional features that make the behavioral test battery
for Ube3a mice highly useful for drug testing. We show
that with the exception of the epilepsy test, all behavioral
experiments can be performed with a single cohort of
mice, which greatly reduces costs as well as the number
of mice needed. In addition, we found that with the
exception of the marble burying task, the behavioral test
battery can be performed twice with the same cohort
while maintaining a phenotype. This makes it possible to
test the efficacy of a drug using a within-subject design.
We confirmed previous studies that the audiogenic
seizure phenotype is a very powerful test to investigate
seizure susceptibility in Ube3a mice [7, 13, 18]. With
this study, this phenotype is now also confirmed in three
independently derived lines: the commonly used Ube3at-
m1Alb line [7], the Ube3amSTOP/p+ (Ube3atm1Yelg) line
[13], and the recently generated Ube3amE113X/p+
(Ube3atm2Yelg) line [23]. Since nearly all Ube3a mice
show this phenotype compared to less than 10% of
wild-type animals, this test has very high power. More-
over, we showed that the phenotype is readily reversible
with the anti-epileptic drug levetiracetam and that the
test is highly suitable for dose finding. The only disad-
vantage of the audiogenic seizure test is that it cannot be
performed on the same animals as used in the behavioral
test battery, since the sensitivity to audiogenic seizures is
exclusively observed in Ube3a mice in the 129S2 genetic
background.
We also observed an effect of genetic background on
the tests of the behavioral test battery. Ube3a mice in
the C57BL/6J background showed a significant pheno-
type in the rotarod, nest building, and marble burying
tests, but no effect of genotype was observed in the open
field test. A significant effect of genotype was found in
the forced swim test, but remarkably, this was in the op-
posite direction. In contrast, Ube3a mice in the 129S2
genetic background showed only a significant deficit in
the forced swim test (in the same direction as F1 hybrid
mice) and no phenotype on any of the other tests of the
behavioral battery. This confirms previous reports that
many of the Ube3a phenotypes are very sensitive to gen-
etic background and not present in 129 lines [8, 9].
There are however several common findings as well as a
few discrepancies between these studies and our study.
With respect to the rotarod [8, 9] and marble burying
phenotype [9], our findings that only Ube3a-C57BL/6J
and Ube3a-F1 hybrid mice show a phenotype are in full
agreement with each other (Huang et al. only tested
Ube3a-C57BL/6J in the marble burying test). With re-
spect to the open field test (distance traveled), the other
two studies also found no phenotype in Ube3a-129 mice,
but in contrast to our findings, they both found a
phenotype in Ube3a-C57BL/6J mice. One major differ-
ence between their and our experimental design is the
time the mice were placed in the open field. Indeed,
when we left the Ube3a-C57BL/6J mice for 30 min in
the open field (instead of the 10 min we used), we found
a nearly significant phenotype in Ube3a-C57BL/6J mice
(p = 0.06; data not shown). With respect to percentage of
time spent in the inner zone of the open field (which is
another measure of anxiety), the other two studies
showed no significant effect of genotype in any of the
genetic backgrounds. Our meta-analysis did however
reveal a significant difference between genotypes in F1
hybrid mice (WT 1.1% versus mutant 0.7% time in inner
zone; p < 0.01), which further indicates that Ube3a-mu-
tant mice are more anxious. However, we note that the
observed difference was small and a significant effect
was only observed in four out of the eight individual ex-
periments. Hence, this measure is not very robust.
Taken all studies into consideration, it is clear that
Ube3a mice in the F1 hybrid 129S2-C57BL/6J back-
ground show the most robust phenotypes, with the not-
able exception of the audiogenic seizure susceptibility
test, which is strictly seen in Ube3a-129S2 mice. The
question arises whether the observed differences be-
tween Ube3a mice in different genetic backgrounds have
any translational significance. The lack of phenotypes of
Ube3a-129S2 mice in most tests could simply reflect the
passive/hypoactive phenotype of these mice, resulting in
a floor effect. However, it could also be that the AS
phenotype is sensitive to genetic background and that
the changes that are observed between individuals with
AS are in part caused by genetic modifiers, rather than
the nature of the mutation. Detailed studies of individ-
uals with recurrent or similar mutations could provide
more insight in that question [53].
To test the translational value of the behavioral test
battery, we decided to re-evaluate the two drugs that
previously were tested in clinical trials involving
individuals with AS: minocycline (trial register
NCT01531582 [20] and NCT02056665 [22]) and levo-
dopa (trial register NCT01281475 [21]). Both drugs
were previously shown to rescue the rotarod impair-
ment of Ube3a mice (see NCT01531582 for minocy-
cline, and [21] for levodopa). In addition, minocycline
rescued the hippocampal LTP deficit of Ube3a mice
[20], whereas levodopa rescued the increased phos-
phorylation of CaMK2 observed in Ube3a mice [21].
We tested the effect of both drugs on all tests of our
behavioral test battery, using the same drug adminis-
tration protocols as used for the original studies. In
addition, we also tested the effect of minocycline
when administered from birth, as previously published
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for the Fragile X mouse model [26]. However, in line
with the clinical trials, we did not observe any effi-
cacy of these drugs when tested on Ube3a mice. Our
finding that minocycline and levodopa are unable to
improve performance on the rotarod is at odds with
aforementioned previous preclinical studies. Failure of
replication could be due to differences in strains or
procedures, although there is full agreement between
our labs with respect to performance of Ube3a mice
on the rotarod and the effects of different genetic
backgrounds on this performance [9]. We think it is
more likely that the rotarod experiments used for the
preclinical studies were underpowered, as our analysis
showed that 14 mice per group are needed for a
well-powered rotarod study using two groups. In the
levodopa study, the authors used 6 different treatment
groups and only 6 mice per group [21]. Such small
sample sizes make the test underpowered and also
very vulnerable for the sex differences that we de-
scribe here. Since the details of the rotarod experi-
ments of the minocycline treatment were not
provided (NCT01531582), we cannot comment on
these discrepancies.
Conclusions
Here, we provided a behavioral test battery with a robust
set of well-characterized Ube3a phenotypes, which allows
researchers to investigate the effects of pharmacological
and genetic interventions involving Ube3a mice. A stan-
dardized set of tests, in combination with a well-defined
genetic background, will also be very useful to compare
data across laboratories. Moreover, using a standardized
behavioral test battery may reduce selective reporting bias
[54]. Future studies should reveal how well the results of
this behavioral test battery can be replicated between dif-
ferent laboratories in which housing and testing environ-
ment is different [55–58]. In addition, robust tests that
capture phenotypes in the domain of cognitive function
should be identified and added to this test battery.
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